Advertisement

Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature

  • Hafize Emine Sönmez
  • Selcan Demir
  • Yelda Bilginer
  • Seza Özen
Original Article
  • 285 Downloads

Abstract

Our aim was to report our experiences of pediatric macrophage activation syndrome (MAS) patients treated with anakinra and to review previous studies reporting anakinra treatment in pediatric MAS patients associated with systemic juvenile idiopathic arthritis (sJIA) or autoinflammatory diseases (AIDs). The study group consisted of pediatric MAS patients due to sJIA or AIDs, followed up in the Pediatric Rheumatology Unit of Hacettepe University between January 2015 and January 2017 and treated with anakinra (anti-IL1). We conducted a systematic review of the published literature involving pediatric MAS patients associated with sJIA or AIDs, treated with anakinra. Thirteen sJIA patients and two AIDs patients were included the study. Nineteen MAS episodes were observed in 15 patients. Anakinra (2 mg/kg/day) was started in with a median 1 day after admission. Clinical symptoms resolved, and laboratory findings normalized within median (minimum–maximum) 2 (1–4) and 6 (4–9) days, respectively after the introduction of anakinra. Steroid treatment was stopped in a median of 10 (4–13) weeks after the initiation of anakinra treatment. Patients were followed up for a median of 13 (6–24) months. Two patients developed recurrent MAS episodes when the anakinra dose was reduced, while the other patients achieved remission. In the literature review, we identified nine articles, describing 35 pediatric MAS patients associated with sJIA or AIDs and treated with anakinra. Except for two, all the patients reached remission. Our study and systematic literature review may help to improve the knowledge on the role of anakinra treatment in the management of MAS.

Keywords

Anakinra Auto-inflammatory syndromes Juvenile idiopathic arthritis Macrophage activation syndrome 

Notes

Authorship contributions

Hafize Emine Sönmez conceptualized and designed the study, carried out the initial analyses, and approved the final manuscript as submitted. Selcan Demir and Yelda Bilginer helped designing the study, collected the data, drafted the initial manuscript, and approved the final manuscript as submitted. Seza Özen coordinated and supervised data collection, reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Compliance with ethical standards

Disclosures

None.

Supplementary material

10067_2018_4095_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 12 kb).

References

  1. 1.
    Morimoto A, Nakazawa Y, Ishii E (2016) Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int Off J Jpn Pediatr Soc 58:817–825CrossRefGoogle Scholar
  2. 2.
    Brisse E, Matthys P, Wouters CH (2016) Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol 174:175–187CrossRefPubMedGoogle Scholar
  3. 3.
    Aytac S, Batu ED, Unal S et al (2016) Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int 36:1421–1429CrossRefPubMedGoogle Scholar
  4. 4.
    Giancane G, Minoia F, Davi S et al (2016) IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol 7:467CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, Zeft A, Spalding S, Gul A, Hentgen V, Savic S, Foeldvari I, Frenkel J, Cantarini L, Patel D, Weiss J, Marinsek N, Degun R, Lomax KG, Lachmann HJ (2017) International retrospective chart review of treatment patterns in severe familial mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/hyperimmunoglobulinemia D syndrome. Arthritis Care Res 69:578–586CrossRefGoogle Scholar
  6. 6.
    Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J (2009) Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 15(4):161–164CrossRefPubMedGoogle Scholar
  7. 7.
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F (2011) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17:23–27CrossRefPubMedGoogle Scholar
  8. 8.
    Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L (2015) Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 34:1333–1339CrossRefPubMedGoogle Scholar
  9. 9.
    Ravelli A, Minoia F, Davi S et al (2016) Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Annals Rheum Dis 75:481–489CrossRefGoogle Scholar
  10. 10.
    Henter JI, Horne A, Arico M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131CrossRefPubMedGoogle Scholar
  11. 11.
    Minoia F, Bovis F, Davi S et al (2017) Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary Hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J Pediatr 189:72–78.e3CrossRefPubMedGoogle Scholar
  12. 12.
    Kelly A, Ramanan AV (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4:615–620CrossRefPubMedGoogle Scholar
  13. 13.
    Kahn PJ, Cron RQ (2013) Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 40:743–744CrossRefPubMedGoogle Scholar
  14. 14.
    Barut K, Yucel G, Sinoplu AB, Sahin S, Adrovic A, Kasapcopur O (2015) Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period. Turk Pediatri Arsivi 50:206–210CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ (2011) Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50:417–419CrossRefPubMedGoogle Scholar
  16. 16.
    Marsili M, Nozzi M, Onofrillo D, Sieni E, Chiarelli F, Breda L (2015) Kikuchi disease, macrophage activation syndrome, and systemic juvenile arthritis: a new case associated with a mutation in the perforin gene. Scand J Rheumatol 44:429–430CrossRefPubMedGoogle Scholar
  17. 17.
    Mohr V, Schulz A, Lohse P, Schumann C, Debatin KM, Schuetz C (2014) Urticaria, fever, and hypofibrinogenemia. Arthritis Rheumatol 66:1377CrossRefPubMedGoogle Scholar
  18. 18.
    Schulert GS, Bove K, McMasters R, Campbell K, Leslie N, Grom AA (2015) 11-month-old infant with periodic fevers, recurrent liver dysfunction, and perforin gene polymorphism. Arthritis Care Res 67:1173–1179CrossRefGoogle Scholar
  19. 19.
    Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ (2015) Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 13:55CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129:750–754CrossRefPubMedGoogle Scholar
  21. 21.
    Singh S, Chandrakasan S, Ahluwalia J, Suri D, Rawat A, Ahmed N, Das R, Sachdeva MUS, Varma N (2012) Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India. Rheumatol Int 32:881–886CrossRefPubMedGoogle Scholar
  22. 22.
    Tristano AG, Casanova-Escalona L, Torres A, Rodríguez MA (2003) Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol 9:253–258CrossRefPubMedGoogle Scholar
  23. 23.
    Minoia F, Davi S, Horne A et al (2014) Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66:3160–3169CrossRefPubMedGoogle Scholar
  24. 24.
    Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34:1133–1138PubMedGoogle Scholar
  25. 25.
    Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E, Erguven M, Poyrazoglu H, Kasapcopur O, Gok F, Akman S, Balat A, Cavkaytar O, Kaya B, Duzova A, Ozaltin F, Topaloglu R, Besbas N, Bakkaloglu A, Arisoy N, Ozdogan H, Bakkaloglu S, Turker T (2011) The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol 29:111–116PubMedGoogle Scholar
  26. 26.
    Unal S, Balta G, Okur H, Aytac S, Cetin M, Gumruk F, Ozen S, Gurgey A (2013) Recurrent macrophage activation syndrome associated with heterozygous perforin W374X gene mutation in a child with systemic juvenile idiopathic arthritis. J Pediatr Hematol Oncol 35:e205–e208CrossRefPubMedGoogle Scholar
  27. 27.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062–1068CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Hafize Emine Sönmez
    • 1
  • Selcan Demir
    • 1
  • Yelda Bilginer
    • 1
  • Seza Özen
    • 1
  1. 1.Department of Pediatrics, Division of Rheumatology, Faculty of MedicineHacettepe UniversityAnkaraTurkey

Personalised recommendations